Answers are grounded in this paper and cite their sources.
Subcutaneous (SC) vedolizumab offers practical advantages over intravenous (IV) administration, but real-world data on switching established patients from IV to SC maintenance therapy remain limited, particularly beyond 12 months. This single-centre, retrospective cohort study evaluated 24 adults with inflammatory bowel disease (IBD) who transitioned from IV to SC vedolizumab maintenance therapy between August 2020 and October 2023. Clinical disease activity indices (SCCAI, HBI), biochemical markers (C-reactive protein, faecal calprotectin) and treatment persistence were assessed at weeks 12, 24 and 48. The cohort comprised 10 patients with Crohn’s disease, 12 with ulcerative colitis and 2 with indeterminate IBD. Treatment persistence was 100% at week 12, 92% at week 24 and 71% at week 48; seven patients (29.2%) discontinued, most often for loss of response ( n = 4). Among continuers, clinical and biochemical disease activity remained stable, and median faecal calprotectin was unchanged across timepoints. No serious adverse events or systemic hypersensitivity reactions were documented; one patient had an injection-site reaction prompting return to IV therapy. In this small, single-centre retrospective cohort, switching from IV to SC vedolizumab was associated with acceptable persistence and stable disease control in appropriately selected patients, particularly those in remission at the time of switch.
No takes yet. Share an insight, caveat, or question.
Salehi et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: